解密人类肠道微生物群与口服抗糖尿病药物之间独特和共同的相互作用

IF 23.7 Q1 MICROBIOLOGY iMeta Pub Date : 2024-03-13 DOI:10.1002/imt2.179

Huahui Ren, Zhun Shi, Fangming Yang, Shujie Wang, Fengyi Yuan, Tingting Li, Min Li, Jiahui Zhu, Junhua Li, Kui Wu, Yifei Zhang, Guang Ning, Karsten Kristiansen, Weiqing Wang, Yanyun Gu, Huanzi Zhong

{"title":"解密人类肠道微生物群与口服抗糖尿病药物之间独特和共同的相互作用","authors":"Huahui Ren, Zhun Shi, Fangming Yang, Shujie Wang, Fengyi Yuan, Tingting Li, Min Li, Jiahui Zhu, Junhua Li, Kui Wu, Yifei Zhang, Guang Ning, Karsten Kristiansen, Weiqing Wang, Yanyun Gu, Huanzi Zhong","doi":"10.1002/imt2.179","DOIUrl":null,"url":null,"abstract":"<p>The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":null,"pages":null},"PeriodicalIF":23.7000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.179","citationCount":"0","resultStr":"{\"title\":\"Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs\",\"authors\":\"Huahui Ren, Zhun Shi, Fangming Yang, Shujie Wang, Fengyi Yuan, Tingting Li, Min Li, Jiahui Zhu, Junhua Li, Kui Wu, Yifei Zhang, Guang Ning, Karsten Kristiansen, Weiqing Wang, Yanyun Gu, Huanzi Zhong\",\"doi\":\"10.1002/imt2.179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":73342,\"journal\":{\"name\":\"iMeta\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":23.7000,\"publicationDate\":\"2024-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.179\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iMeta\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/imt2.179\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

2 型糖尿病患者服用口服抗糖尿病药物（OADs）后，肠道微生物群会发生不同的共同变化，其中阿卡波糖和小檗碱对肠道微生物群的影响大于二甲双胍、维达列汀和格列吡嗪。基线肠道微生物群与 OADs 的治疗反应密切相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs

The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

iMeta

CiteScore

10.80

自引率

0.00%

发文量